Abstract
Abstract
Background
Epilepsy secondary to acquired immunodeficiency syndrome (AIDS) can be challenging to manage. The potential interactions between antiretroviral drugs and antiepileptic drugs may result in the failure of both treatments. Therefore, it is crucial to develop more effective strategies to enhance the clinical outcomes of patients.
Case presentation
We report a case of epilepsy secondary to AIDS. After administration of Bacteroides Fragilis 839 (BF839), the secondary generalized tonic-clonic seizures disappeared, the frequency of complex partial seizures decreased by 70%, and the duration of each episode was shortened. Additionally, long-term diarrhea associated with antiretroviral therapy for AIDS resolved, and the syphilis serofast reaction turned negative. No serious adverse reactions were observed during the three-year follow up.
Conclusions
This case report suggests that the specific gut microbiota preparation could possibly improve refractory epilepsy in HIV patients while also potentially alleviating adverse reactions to antiretroviral drugs and concurrent syphilis infection. Our case may provide a new perspective for the treatment of HIV infection/AIDS.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Ssentongo P. Prevalence and incidence of new-onset seizures and epilepsy in patients with human immunodeficiency virus (HIV): Systematic review and meta-analysis. Epilepsy Behav. 2019;93:49–55.
2. Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George J, et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012;78(2):139–45.
3. Zhang JJ, Yu LX, Xu LZ, Wang WY, Zhang HJ, Pan ZH, et al. Isolation and identification of a non-toxic and fragile Bacteroid strain. Ningxia Med J. 1991;13:216–8.
4. Zhang JJ, Zhang HM, Zhang Y, Zhang HG, Bi L, Zhang XC, et al. Clinical application study of Bacteroides fragilis (BF839) bacterial solution. Chin J Biol Prod. 1995;8:63–5.
5. Feng SZ, Zhang HP. Research progress on Bacteroides fragilis. Microbiol Bull. 2015;42:1366–71.